For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
Plans to double its manufacturing footprint to bolster the growth
-0001_256_384.jpg){kind=logo}
The eyecirque under eye skin brightening supplement is a unique composition of scientifically proven essential antioxidants, vitamins and minerals
Theruptor Novo is a best in class patented product which provides an optimum healing environment and addresses the concerns of chronic wound dressing
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
Subscribe To Our Newsletter & Stay Updated
